Aethlon Medical surges on research partnership with NAMSA

Aethlon Medical

30/01/2023 16:53

** Shares of drug developer Aethlon Medical Inc  AEMD.O 
jump 40.8% to 66 cents - set for their highest one-day pct. gain
in over 5 months, if gains hold 
    ** Co enters into an agreement with private, medical
device-focused contract research organization NAMSA to oversee
the clinical trials testing its blood filtration device for
treatment of cancer 
    ** Under the deal, NAMSA will manage the study of the
device, hemopurifier, for patients in the U.S. and Australia
with various types of cancer- AEMD
    ** AEMD plans to begin trials for hemopurifier in Australia 
    ** Including session moves, AEMD has fallen ~54.4% over the
past 12 months
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))